Fed. Circ. Urged To Undo Amgen's Win Over Cancer Drug IP
An Indian drugmaker is asking the Federal Circuit to overturn a lower court decision upholding Amgen's patents for its anti-cancer drug Kyprolis, saying the ruling improperly "converts" a narrow claim to...To view the full article, register now.
Already a subscriber? Click here to view full article